Ozempic and Mounjaro are FDA-approved prescription brand families used in type 2 diabetes care, but they do not contain the same active ingredient. Ozempic contains semaglutide and has injectable and newer tablet products; Mounjaro contains tirzepatide and is supplied in injectable presentations. Comparing them requires separating diabetes clinical evidence from obesity-branded Wegovy and Zepbound discussions.
There is relevant direct evidence: SURPASS-2 studied adults with type 2 diabetes taking metformin and compared three once-weekly tirzepatide doses against injectable semaglutide 1 mg over 40 weeks. It assessed HbA1c and other outcomes under specified trial conditions. Its findings are informative, but cannot be extended without qualification to Ozempic tablets or every currently labeled semaglutide dose.
This guide focuses on branded indications, actual diabetes study endpoints, safety, product-form differences and legitimate U.S. prescription paths. Prices, self-pay promotions and insurer-specific financial calculations remain on a separate comparison page to avoid duplicating the commercial pricing intent.
Ozempic contains semaglutide, which acts at GLP-1 receptors; Mounjaro contains tirzepatide, which targets GIP and GLP-1 receptors. The ingredient difference means these products are not interchangeable brands or simple generic alternatives.
Ozempic now includes tablets and injections; the Mounjaro products discussed here are injectable. For ingredient-level differences independent of branding, use semaglutide vs tirzepatide.
Compare the named product rather than a broad drug-class listing. The table distinguishes FDA-labeled use, supply form and legitimate access; no row establishes automatic substitutability or personalized prescribing. SURPASS-2 reported mean HbA1c change of −1.86 percentage points for injectable semaglutide 1 mg versus −2.01 to −2.30 for the studied tirzepatide doses at 40 weeks. Do not extrapolate to Ozempic oral tablets, different doses or all populations.
For product and availability checks, confirm the exact FDA label and prescription with a licensed clinician or pharmacist. The table is a decision aid rather than a live price feed or a dosing conversion chart.
| Comparison topic | Ozempic | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | GIP and GLP-1 receptor agonist |
| Forms | FDA-approved tablets and injections | Prescription injections |
| Direct head-to-head evidence | SURPASS-2: 1-mg weekly semaglutide arm | SURPASS-2: 5-, 10-, 15-mg weekly arms |
| Primary trial context | Type 2 diabetes, metformin background, 40 weeks | Same trial and background therapy |
| Brand-specific access | Exact Ozempic product and prescription | Exact Mounjaro product and prescription |
Both brands have FDA-approved treatment roles in type 2 diabetes. Ozempic injection and Ozempic tablets differ in certain presentation-specific labeled risk-reduction uses, while Mounjaro has its own label and population restrictions.
Do not assume Ozempic or Mounjaro is generically FDA-approved for obesity treatment because weight loss may be observed in trials. Separate weight-management brands Wegovy and Zepbound have their own approvals.
SURPASS-2 enrolled 1,879 adults with type 2 diabetes receiving metformin, randomized among tirzepatide 5, 10 or 15 mg weekly and injectable semaglutide 1 mg weekly. The study followed participants for 40 weeks and primarily examined change in HbA1c.
At week 40, reported mean HbA1c reductions were 2.01, 2.24 and 2.30 percentage points for tirzepatide doses, versus 1.86 percentage points for semaglutide 1 mg. These trial-specific findings do not compare all current Ozempic strengths, Ozempic tablets or obesity indications.
SURPASS-2 also reported greater mean reductions in body weight for its tirzepatide arms than the studied semaglutide arm. In this context, weight was measured in people with type 2 diabetes receiving particular regimens.
A reader interested principally in weight-management brands should instead examine Wegovy vs Zepbound and its distinct obesity evidence; a diabetes-trial weight result does not transform the diabetes brands into products with the same obesity labeling.
Gastrointestinal adverse events were common in SURPASS-2, with rates and severity depending on the actual regimen and population. Both ingredient families carry boxed warnings related to thyroid C-cell tumors, along with other FDA-labeled contraindications and precautions.
Clinicians consider other glucose-lowering therapies, possible hypoglycemia risk when combined with certain drugs, kidney or gastrointestinal problems and individual history. It is inappropriate to infer clinical suitability solely from a trial efficacy table.
The semaglutide comparator in SURPASS-2 was a specified weekly injectable dose, not the current Ozempic oral tablet. This matters because oral formulations have different labeled dosing, absorption instructions and package units.
Mounjaro’s product-specific injection presentation must also match the prescription. A pharmacy cannot replace an Ozempic oral or pen order with Mounjaro through an unsupervised substitution.
Identify the specific SURPASS-2 comparator first: weekly semaglutide 1 mg and defined weekly tirzepatide arms, all in patients receiving metformin. Do not relabel this as an Ozempic tablet study.
Then verify which current FDA indication and form the prescriber is considering; a study HbA1c advantage does not independently establish payer coverage, safe substitution or the retail package that will be dispensed.
A patient may encounter a summary claiming Mounjaro beat Ozempic and then compare that statement with a newer Ozempic tablet quote. The key correction is that SURPASS-2 tested injectable semaglutide 1 mg against named injectable tirzepatide regimens. Use the Ozempic tablet page to identify the oral product rather than ascribing the injection trial’s result to it.
For eligibility and administrative terms, the Ozempic insurance page addresses form- and plan-specific rules. No favorable trial result, label claim or drug-class comparison is proof of a covered claim or an available pharmacy package.
Start with the FDA-labeled diabetes indication, intended presentation and prescriber assessment. The respective purchase paths are buy Ozempic and buy Mounjaro.
Clinical comparison should not be used to select a substitute without a new authorized prescription. Avoid unapproved imported or compounded alternatives marketed as equivalent.
Licensed pharmacies must validate the exact branded product and prescription, including route, supply and any remaining refills. A comparison does not establish live availability at a particular pharmacy.
Use the pharmacy verification checklist when evaluating remote pharmacy claims.
Detailed price, manufacturer self-pay and payer comparisons live at Ozempic vs Mounjaro price. This article does not import obesity-brand Zepbound or Wegovy prices into the diabetes comparison.
Prior authorization criteria may differ by drug and formulation, and neither clinical trial outcomes nor FDA approval guarantee plan coverage.
This article preserves trial populations, assigned injectable regimens and the HbA1c endpoint without making personalized clinical recommendations. Review current FDA labels for additional indications and restrictions.
Some linked commercial resources may compensate the site; that does not change the independence of prescribing and pharmacy decisions.
No. Ozempic contains semaglutide; Mounjaro contains tirzepatide.
SURPASS-2 compared weekly semaglutide 1 mg against specified tirzepatide doses in adults with type 2 diabetes.
The primary comparison was the change in HbA1c over 40 weeks under the trial’s conditions.
No. Its semaglutide comparator was a weekly injection regimen.
No. It was a diabetes study and does not replace Wegovy-versus-Zepbound obesity trials.
Yes. Both are prescription-only products in the United States.
No. They are different active ingredients and require an appropriate prescribing decision.
No. Coverage depends on the exact product, plan, indication and authorization criteria.
No. Trial group averages do not predict an individual response or determine treatment suitability.